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Background: Human papillomavirus (HPV) is a common sexually transmitted virus that can lead to severe diseases
in both women and men. Today, HPV vaccination is offered to females only across Europe. We aimed to examine
parental attitudes to HPV vaccination of their sons given brief information about HPV in both genders.
Methods: A literature study on acceptability of male HPV vaccination was carried out to inform the construction of
a study questionnaire. Following up on a Danish study from 2012, this questionnaire was applied in 1837 computer
assisted interviews with parents of sons in the UK, Germany, France and Italy. In each country, the parents were
representative in terms of geographical dispersion, city size and age of sons in the household. The applied
questionnaires took the varying vaccination policies and delivery systems into account. The data were analysed
pooled and for each country using significant statistical tests (chi-2) with a 95 % confidence interval.
Results: Approximately ¾ of parents in the UK, Germany and Italy were in favour of HPV vaccination of their sons.
In France, this applied to 49 % of respondents. Favourable parents wanted to protect their sons from disease and
found gender equality important. Parents in doubt about male HPV vaccination needed more information about
HPV diseases in men and male HPV vaccination; Rejecting parents were generally sceptical of vaccines and feared
vaccination side-effects. Parents in countries with active vaccination policies (UK and Italy) tended to trust the
importance of national vaccination programmes. Parents in countries with passive vaccination strategies (Germany
and France) had greater need for information from health care professionals (HCP) and public health authorities.
Conclusion: Given brief information about HPV in both genders, parental acceptance of HPV vaccination of sons is
as high as acceptance levels for girls. All parents should be informed about HPV to make informed decisions about
HPV vaccination for their children. There is a need for joint efforts from public health authorities and HCPs to
provide parents with such information.
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Preventive health behaviourBackground
Female vaccination against human papillomavirus (HPV)
infection is included in vaccination calendars across the
EU with the primary aim to prevent cervical cancer
(CC). Two HPV vaccines exist, of which quadrivalent
HPV vaccination (Gardasil) protects against oncogenic
HPV 16 and 18 (causing around 70 % of CC) as well as
types 6 and 11 causing most cases of genital warts (GW)* Correspondence: glm@anthroconsult.dk
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creativecommons.org/publicdomain/zero/1.0/[1]. The bivalent vaccine (Cervarix) protects against
HPV types 16 and 18. Oncogenic HPV, particularly types
16 and 18, also cause other cancers in addition to CC.
HPV is involved in around 50 % of vulva, vaginal and
penile cancers, 90 % of anal cancers, and 60–70 % of
oro-pharyngeal cancers [2]. In Europe, approximately
340.000 cases per year of HPV vaccine preventable dis-
eases affect men and women, respectively [3]. The num-
ber of non-cervical cancers is almost similar to CC [4].
A large clinical study has shown that quadrivalent
HPV vaccine is safe and effectively reduces ano-genitalccess article distributed under the terms of the Creative Commons Attribution
by/2.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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males [5, 6]. This vaccine has a gender neutral indication
and is already recommended for use in males in the
USA, Canada and Australia. While the European Centre
for Disease Prevention and Control (ECDC) finds the
clinical evidence on the efficacy and safety of male HPV
vaccination promising, it calls for further research
including studies of HPV vaccine acceptability among
parents and health care providers (HCP) [7]. In the EU,
Austria recommends universal HPV vaccination but has
yet to implement it in a vaccination programme. A
permissive recommendation for male HPV vaccination is
issued in the German region of Saxony and, more
recently, in Ireland [8–10].
Previous studies of attitudes towards male HPV
vaccination were mainly from USA and, until recently,
most have focused on the prevention of CC [11]. Over-
all, it has been shown that parental attitudes are
important to the uptake of HPV vaccination, and that
most parents view vaccination of both sexes
favourably, with positive views on other vaccines,
recommendations from HCP and knowledge about
HPV and related disease acting as positive factors.
Acceptance is related to perceptions of disease risks
(susceptibility and severity) and benefits and risks of
vaccination [12–15]. Males are particularly accepting
of a vaccine with direct benefits for themselves. The
greatest barrier towards male HPV vaccination among
males, parents and HCPs is the perceived absence of
direct benefits for males [11, 16, 17]. Given that HPV
vaccine was mainly marketed as a CC vaccine for girls,
with little reference to the sexual transmission of the
virus, awareness about HPV related diseases in men
and the perceived relevance of vaccinating males is low
[18–25].
Following up on a study of parental attitudes towards
male HPV vaccination in Denmark [17], the present
study examined parental views on HPV vaccination of
sons in France, Germany, Italy and the UK. The aim was
to gain knowledge about drivers and barriers to
European parents’ acceptance of male HPV vaccination
including socio-economic factors related to acceptability.
We aimed to investigate attitudes in parents of sons at
an age in which girls in their country are recommended
HPV vaccination in national vaccination calendars
(NVC) or national immunization programmes (NIP). As
the information given in connection with a survey is
decisive to acceptance rates, we presented parents with
brief oral information about HPV transmission and
related diseases in males and females before asking them
about their attitudes towards HPV vaccination of their
sons. To our knowledge, this is the first study using this
approach to examine parental views on male HPV
vaccination across several European countries.Methods
A literature study was carried out examining HPV vaccine
acceptability. The results guided the construction of a
questionnaire to be used in interviews with parents of sons
in the UK, France, Germany and Italy. The questionnaire
was formulated with an aim to capture relevant issues in
all four European countries with their varying health care
systems and HPV vaccination delivery structures.
In the UK, HPV vaccination of 12–17 year-old girls is
included in the free NIP in which vaccines are mainly
delivered through a school-based programme. In Italy,
12 year-old girls are included in the free NIP, though
some regions also vaccinate additional cohorts; some at
a reduced price for targeted groups. In Germany, HPV
vaccination of girls aged 12–17 is recommended,
implying a mandatory reimbursement from the sick
funds of which some also reimburse HPV vaccination of
additional cohorts. In France, the recommended age for
female vaccination was lowered from 14 to 11 years
(with catch-up for <20 year-olds) at the beginning of
2013, with reimbursement in place by May 2013. In
France, 65 % of the vaccine cost is publicly reimbursed
while private health insurers cover the remaining 35 %.
While the UK and Italy have organised NIPs, HPV vac-
cination in Germany and France is in NVCs implying op-
portunistic vaccination [26].
Respondents were parents of 12–17 year-old sons in
the UK and Germany, parents of 12 year-old sons in
Italy, and parents of 11–14 year-old sons in France. 450
telephone interviews were carried out with parents in
the UK and 454 interviews in France, using computer
assisted telephone interviews (CATI); 482 face-to-face
interviews using the same questionnaire and computer
assisted personal interviews (CAPI) were carried out in
Germany, and 451 in Italy, where the number of boys in
the relevant age brackets is low. The sample sizes in
each country were based on the incidence rate of par-
ents of sons in the relevant age brackets which is be-
tween 4–5 %. The purpose of this was twofold: firstly, it
enabled comparison with the former study conducted
among 450 Danish parents of 12–15 year-old sons [17];
secondly, a minimum of 450 respondents per country is
statistically valid to highlight significant differences be-
tween countries. With a sample size of 450 respondents,
the confidence interval is approximately 4.2 %. Quota
sampling was applied to target this specific group of
respondents who were dispersed representatively corre-
sponding to regional and urban/rural places of residence
according to the National Institute of Statistics and Eco-
nomic Studies (INSEE) in France, the Office for National
Statistics (ONS) in the UK, the Statistisches Jahrbuch in
Germany, and the Italian National Statistics Institute
(ISTAT), respectively. As such, the samples were repre-
sentative of parents of sons in the relevant age groups of
Lee Mortensen et al. BMC Public Health  (2015) 15:624 Page 3 of 10each country. In France, the sample was randomly ex-
tracted from purchased Yellow Pages files. In the UK,
sample recruitment used 50 % omnibus and 50 % White
Pages. In Germany and Italy, respondents were recruited
by interviewers going door-to-door, and interviews con-
ducted in respondents’ homes. All interviews continued
until the quotas on sons’ age and geographical dispersion
were reached. Interviews were carried out by Ipsos
Healthcare from May 15th – June 4th 2013. No personal
information was collected about the participants except
from what they chose to volunteer during the interviews.
The participants were assured of their full anonymity
and all gave oral consent prior to commencing the inter-
views. As such, and due to the market research approach
that was applied, the study did not require ethics com-
mittee approval in any of the countries [27–32].
Interviews were carried out with parents ‘having an
equal or primary responsibility for health-related deci-
sions regarding the children in the household’. Brief oral
information was given to respondents who were then
asked about the number and gender of children in the
household, acceptance of female HPV vaccination,
compliance with the NIP/NVC for children, attitudes
towards male HPV vaccination to reduce the overall
transmission of HPV in society, attitudes towards HPV
vaccination of own son(s) and sources of recommendation
mostly listened to regarding vaccination. Income level, edu-
cational level and postal code was also registered (Fig. 1.
Questionnaire applied in the United Kingdom).
The data was analysed systematically for each individual
country and pooled for the four countries. Significant stat-
istical differences were performed with a 95 % confidence
interval. Systematic analysis breakdown was performed on
gender, income level, educational level, region, place of liv-
ing, presence of girls in the household, HPV acceptance in
girls, attitudes towards HPV vaccination to reduce the over-
all transmission, and sources of recommendation most lis-
tened to. Following Q5 asking about parents’ attitudes
towards HPV vaccination of their sons (Table 1), correl-
ation analysis was carried out on questions Q6 and Q7
regarding the main reasons for parents to accept, reject or
have doubts in order to examine the key variables, drivers
and barriers to male HPV vaccination (Additional file 1.
Correlation analysis of reasons to accept (Q6), have doubts
or reject (Q7) HPV vaccination of sons).Fig. 1 Questionnaire applied in the United KingdomResults
Most respondents (72–89 %) were mothers and the re-
spondents were nationally representative with regard to
varying educational and income levels, age, number and
gender of children, urban/rural and region of residence
(Table 1. Parental acceptability of HPV vaccination of
males, sons and daughters).
Table 1 Parental acceptability of HPV vaccination of males, sons and daughters
Question Results in % UK Germany Italy France
Q5. Would you want your son to be
vaccinated against HPV?
Yes 75 72 70 49
p = <0.001 p = <0.001 p = <0.001
Yes, even if only partially reimbursed - 19 8 -
Yes, even if I pay myself 7 2 2 -
(450 £) (450 €) (515€)
No 3 20 15 34
p = <0.01 p = <0.01 p = <0.01
Uncertain 22 8 15 17
p = <0.001 p = <0.001 p = <0.001
Q8. Do you think that boys should be
vaccinated against HPV to reduce the
overall transmission of HPV in the population?
Yes 85 73 70 82
p = <0.1 p = <0.1
No 2 20 19 14
p = <0.001 p = <0.001 p = <0.001
Uncertain 13 7 11 4
Q4. Attitudes towards the childhood
immunisation programme
Adherence 89 77 77 78
p = <0.001
Partial adherence 9 22 21 19
Non- adherence 1 1 2 1
Uncertain 1 - - -
Q3a. Will you let your daughter(s) aged
below X (the eligible age) receive HPV
vaccination when she/they reach(es) the eligible age?
Yes 92 67 66 65
p = <0.001
No 2 13 11 14
Uncertain 6 20 23 21
p = <0.01 p = <0.01 p = <0.01
Q3b.Has/have your daughter(s) in the
eligible age received HPV vaccination?
Q3b2. If not, do you think she/they will be vaccinated?
Yes 67 36 75a 9
No 27 64 25 91
Uncertain 6 - - -
Intend to vaccinate 67 36 - 56
Q3c. Has/have your daughter(s) older
than X (the eligible age) received HPV vaccination?
Yes 44 44 51 47
No 29 56 49 48
p = <0.01 p = <0.01 p = <0.01
Uncertain 27 - - 5
Q3d. What is your attitude towards HPV
vaccination of x year-old girls (asked only
to parents with no daughters)
For 82 (vs.IT) 75 73 75
p = <0.05
Against 2 17 14 11
Uncertain 16 8 13 14
p = <0.01 p = <0.05 p = <0.05
a Low sample size: N = 4 respondents had 12 year-old daughters
- Implying that the response is not an option for the country in question or that no respondents answered this option
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to reduce the transmission of HPV in society (70–85 %)
and of their own sons (49–75 %). Number and gender of
children in the household, gender of respondent, level of
education and income were generally not significant
variables related to acceptability. Exceptions were that, inGermany, region of residence was a significant variable,
whereas town size was related to acceptability in Italy,
and having a daughter played a minor role in France.
In all countries, the main correlates of favourable
attitudes toward HPV vaccination of sons were positive
attitudes toward other childhood vaccines in the NIP/
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ation to reduce the overall transmission of HPV in soci-
ety. Hence forward, we shall name parents in favour of
HPV vaccination of their sons ‘approvers’, parents uncer-
tain about HPV vaccination of their sons ‘doubters’, and
parents against HPV vaccination of their sons ‘rejecters’.
In all countries, doubters and approvers had similar par-
ticipation rates in the NIP/NVC, whereas rejecters had
significantly lower uptake of childhood vaccines.UK
Among the four countries, parents in the UK were the
most favourable towards HPV vaccination of their sons
(75 %) and toward generalised male HPV vaccination
(85 %). Parents in the UK had the highest compliance
with the NIP, the highest number of eligible daughters
vaccinated against HPV, and of unvaccinated eligible
daughters intended to be vaccinated in due time.
Germany
In Germany, 72 % of parents were in favour of HPV vac-
cination of their sons. Acceptability was significantly
higher in Northern (82 %) and Eastern Germany (91 %).
Seventy percent were in favour of vaccinating males to
reduce the transmission of HPV in society. Seventy-
seven percent stated to have given their children all
vaccines in the NVC. These figures were not matched by
HPV vaccination rates among daughters, however. Only
36 % of eligible girls, and 44 % of older daughters, had
been HPV vaccinated.
Italy
In Italy, 70 % of parents were in favour of having their
sons receive HPV vaccination. Parents living in mid-
sized cities were significantly less favourable (55 %).
77 % of parents had fully complied with the NIP, and
73 % were in favour of general male HPV vaccination
to reduce the transmission of HPV in the population.
In Italy, 51 % of parents of daughters above the age of
12 stated that these had been vaccinated against HPV.
France
In France, 49 % of the parents were in favour of HPV
vaccination of theirs sons, while 34 % rejected. This
acceptance rate is significantly lower than in the other
three countries. In contrast, 78 % of French parents
stated full compliance with the NVC, and 82 % were in
favour of generalized male HPV vaccination. Only 9 % of
parents stated that daughters in the eligible age bracket
(11–14 year-old) received HPV vaccination which is
unsurprising given the recently lowering of the targeted
age group. 56 % intended eligible daughters to be vacci-
nated. The uptake among daughters aged >15 years was47 %. Parents of daughters were more often doubters
than parents without daughters.
Pooled analysis
Given brief oral information on HPV-related disease in
males, most parents in Germany, UK and Italy were in
favour of HPV vaccination of their sons (70–75 %). In
the UK, a school based vaccination programme plays a
key role in the high uptake of all childhood vaccines in
the NIP, and parental attitudes toward male HPV
vaccination were correspondingly high. In Italy, attitudes
toward HPV vaccination of sons were as favourable as
attitudes towards female HPV vaccination and the NIP,
in general. In Germany, parents mostly stated to be in
favour of male HPV vaccination, but a high number of
parents rejected HPV vaccination of their sons, particu-
larly in Western Germany. HPV vaccination of daugh-
ters was low. In France, significantly less (49 %) parents
were in favour of HPV vaccination of their sons despite
favourable attitudes towards generalised male HPV
vaccination. The low acceptance rates for HPV vaccin-
ation of sons matched the acceptance of daughters’ HPV
vaccination (Table 2. Parents' reasons to accept, reject or
have doubts about HPV vaccination of sons).
In the UK and France, main reasons to be in favour of
HPV vaccination of one’s own sons were to protect them
from (any) STD (59/63 %, respectively). Next, some par-
ents stated that they wanted to protect their sons’ future
partners (24/19 %). In the UK, 23 % of parents said they
welcomed all vaccines. In France, 25 % welcomed any
protection against cancer.
A broader range of answers were given in Germany
and Italy. Here, equal rights of HPV vaccination was the
main reason (52 and 65 %, respectively), and shared
responsibility to prevent STDs was also significantly
more often stated as reasons to be favourable (44/53 %)
than in the UK and France. In Germany and Italy, any
protection against cancer was welcomed (by 51/49 %),
and in Italy, 59 % said their son was also being at risk of
HPV infection.
While fear of vaccination side effects and being against
(too many) vaccines were main barriers to rejecters, and
particularly widespread in Germany and France, lack of
knowledge about HPV related diseases and HPV
vaccination were significantly more frequent barriers to
doubters in all countries. In France and Italy, lack of
recommendation from HCPs was also important (please
find in Additional file 1 the correlation coefficients of
the correlation matrix for Q6 and Q7 regarding main
reasons to accept, reject or have doubts about HPV
vaccination of sons) (Table 3. Are there any people or
authorities whose recommendations you particularly lis-
ten to in connection with health-related issues such as
this vaccination).
Table 2 Parents’ reasons to accept, reject or have doubts about HPV vaccination of sons
Unassisted
question
UK Germany Italy France
Approvers
(Q6)
To protect my son against
STD (59 %)
Both sexes should have equal
rights to vaccination (52 %) p value
<0.001
Both sexes should have equal
rights to vaccination (65 %) p value
<0.001
To protect my son from STD
(63 %)
To protect my son’s future
partners (24 %)
I welcome any protection of my
children against cancer (51 %)
Both sexes are equally responsible
for preventing STD (53 %)
I welcome any protection of
my children against cancer
(25 %)
I welcome all vaccines for
children (23 %)
Both sexes are equally responsible
for preventing STD (44 %)
My son is also at risk of HPV
infection (50 %)
To protect my son’s future
partners (19 %)
My son is also at risk from
HPV infection (19 %)
Fear of HPV related diseases if not
vaccinated (42 %)
I welcome any protection against
cancer (49 %)
If HPV vaccination is




I don’t know enough about
HPV vaccination (54 %)
I don’t know enough about HPV
vaccination (69 %)
I don’t know enough about HPV
related diseases (83 %)
I fear side effects (45 %)
I don’t know enough about
HPV related diseases (53 %)
I fear side effects (61 %) I don’t know enough about HPV
vaccination (67 %)
I don’t know enough about
HPV related diseases (38 %)
I fear side effects (25 %) I don’t know enough about HPV
related diseases (56 %)
I fear side effects (62 %) Lack of recommendation from
HCP (31 %)
I prefer that my son makes
his own decision later
(13 %)
I am against (too many) vaccines
(39 %)
Lack of recommendation from HPC
(44 %)
I don’t know enough about
HPV vaccination (28 %)
Rejecters
(Q7)
It goes against my cultural/
religious beliefs (39 %)a
I fear side effects (64 %) I fear side effects (76 %) I fear side effects (46 %)
Other (31 %)b I don’t know enough about HPV
vaccination (57 %)
I am against (too many) vaccines
(73 %)
Lack of recommendation from
HCP (23%)
I fear side effects/my son is
too young (23 %
respectively)
I am against (too many) vaccines
(54 %)
I don’t know enough about HPV
related diseases (55 %)
I don’t know enough about
HPV vaccination (21 %)
I don’t know enough about
HPV related diseases (15 %)
I don’t know enough about HPV
related diseases (47 %)
I don’t know enough about HPV
vaccination (51 %)
I am against (too many)
vaccines (17 %)
aNote the low sample size for UK rejecters: 3 % of all UK respondents.
bMost ‘Other’ responses from the UK fit in preexisting response options and mainly dealt with vaccine safety and efficacy concerns, the vaccine being too ‘new’ to
be considered safe, and the son being too young
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of advice regarding vaccination. In Germany and Italy,
paediatricians also play a very important role, whereas in
the UK, the NHS has great authority. In Germany and
France, family, friends and media had some influence. In
Italy, this applied to the Local Health Units (Azienda
Sanitaria Locale). Doubters in all countries listened (at
least) as much as approvers to GPs and paediatricians
(and the NHS in the UK). In Germany, doubters also
listened significantly more to friends and social media,
however. Overall, rejecters listened less to HCPs and
more to family and social media.
Discussion
HPV infected men are at risk of developing HPV related
diseases and they increase the risk of infection in
women. A normalisation of HPV vaccination may
improve uptake and herd-immunity in women as well as
men [3, 16, 24, 33–36]. Besides the issue of HPV related
morbidity and mortality in both sexes, ethical issues
regarding social justice (considerations of MSM anddisadvantaged populations) and gender equality should
be considered [37, 38]. Today, a major challenge to HPV
vaccination is to transform the image of a females-only
cervical cancer vaccine to a universal childhood vaccine.
The present study had the strength of including a large
number of decision-making parents of sons at a relevant
age for HPV vaccination across four countries in the EU.
The analysis allowed us to gain knowledge about drivers
and barriers to parental attitudes towards male HPV vac-
cination and significant factors related to acceptability.
As the study did not include clinical register data, how-
ever, intentions to let unvaccinated sons and daughters
vaccinate against HPV may be over-stated; the same
limitation applies to the stated compliance with the
NIP/NVC including HPV vaccination of daughters. Fur-
thermore, the data collection methods differed in the
four countries lowering the comparative strength of the
study. Answers from face-to-face interviews were more
comprehensive, but the presence of an interviewer may
have biased respondents towards more positive attitudes
towards (HPV) vaccination. Responses given to the
Table 3 Are there any people or authorities whose recommendations you particularly listen to in connection with health-related
issues such as this vaccination
Unassisted
Question
UK Germany Italy France
Total (Q9) GP (46 %) GP (72 %) GP (75 %) GP (69 %)
p <0.001 p <0.001 p <0.001
National Health Service
(NHS) (30 %)





Azienda Sanitaria Locale (Local
Health Unit, AZL) (19 %)
Uncertain (10 %)
Uncertain (23 %) Friends and family (23 %
respectively )
Gynecologist (17 %) Social media (8 %)
Approvers
(Q9)
My GP (46 %) GP (74 %) GP (78 %) GP (70 %)
p <0.001 p <0.001 p <0.001
NHS (31 %) Pediatrician (48 %) Pediatrician (65 %) Family (13 %)
Other (31 %) Krankenkasse (sick fund)
(30 %)
Azienda Sanitaria Locale (AZL)
(23 %)
Uncertain (9 %)
Uncertain (23 %) Family members (25 %) Gynecologist (20 %) Social media (8 %)
Doubters (Q9) GP (51 %) GP (68 %) Pediatrician (73 %) GP (78 %)
p <0.01 p <0.001
NHS (30 %) Pediatrician (45 %) GP (70 %) Pediatrician (9 %)
p <0.001 p <0.001
Uncertain (22 %) Friends (33 %) National health authorities (29 %) Family (8 %)
p <0.05
Other (22 %) Social media (28 %) Azienda Sanitaria Locale (AZL)
(14 %)
The public health authorities or a
gynecologist (7 % respectively)
p <0.05
Rejecters (Q9) Uncertain (46 %) GP (66 %) GP (67 %) GP (62 %)
p <0.001 p <0.001 p <0.001
Other (39 %) Pediatrician (36 %) Pediatrician (61 %) Uncertain (16 %)
GP (15 %) Family (23 %) National health authorities (19 %) Family (10 %)
Social media (15 %) Friends (11 %) Gynecologist (16 %) Social media (9 %)
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were fewer but likely to include the most pertinent is-
sues to the respondents. As quota sampling is a non-
random methodology implying that not every everyone
gets a chance of participation, a selection bias may be in-
volved. With face-to-face interviews, in particular,
favourable respondents may me more likely volunteer to
participate creating a possible bias towards positive atti-
tudes. Finally, the sample sizes imply that some country
specific sub-categories involve only few respondents thus
lowering the strength of the cross-tab analysis.
Still, our results support previous findings that direct
protection attributes is a central driver to parental
acceptability of HPV vaccination of sons [11, 17, 33]. In
addition, we found that many parents consider gender
equality in health exceedingly important, and that given
information about HPV vaccination and the total benefits
of male HPV vaccination, parental acceptability rates are
similar to vaccine acceptability for daughters [3, 38, 39].Parents’ reasons to doubt or reject HPV vaccination of
their sons differed significantly. Doubters particularly
called for information about HPV related diseases and
HPV vaccination. Rejecters had more pronounced
concerns about side effects and vaccines, in general. A
central means to augment the uptake of HPV vaccination
may be to engage in efforts to improve awareness and
knowledge about HPV, specifically, but also improving
trust in vaccines, in general [40]. According to the ECDC
(2012), parents and prescribers (HCP) need to be
provided with appropriate evidence-based information on
the benefits and risks of HPV immunisation.
Barriers to vaccination are not the same whether a
person is hesitant, omitting or opposed for philosophical
reasons [20]. Broadly speaking, barriers to a vaccine can
be logistical and/or cognitive. Cognitive issues include
knowledge and perceptions. Vaccine attitudes are related
to perceptions of benefits and risks of the vaccine and
the targeted diseases, and these are linked to local public
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media coverage, not only of HPV vaccination, but also of
vaccines against Hepatitis B in France, MMR in the UK,
and the pandemic flu in 2009 contributed to create a
fear of vaccination disproportional to the fear of the pre-
ventable diseases [20, 33, 41–44]. While anti-vaccination
convictions are only found in 3–7 % of the population
[45], hesitancy has become a major issue, as people in-
creasingly seek answers to their concerns in order to bal-
ance the pros and cons of vaccination. This has created
a growing need for objective information about vaccines
from public health authorities and HCPs [33]. Local
studies confirm our results that GPs and paediatricians
play a major role in shaping parents’ perceptions of
vaccines [16, 20, 21, 38, 43, 46–50].
While HPV vaccine knowledge is crucial, some
scholars have argued that structural incentives and barriers
(cost and accessibility) may have even greater impact on
uptake [16]. The highest HPV vaccine uptake rates are
found in countries with free school-based (opt-out) or
national public health programmes such as the UK where
80 % of the target group have been vaccinated. In Italy,
there is no school-based programme, yet some regions
have obtained similar high coverage rates through
extensive planning and action from Local Health Units,
e.g., 80.7 % in the Basilicata region where parents of
12 year-old girls were called directly [51]. In France and
Germany, it has been suggested that school-based
programmes could also improve HPV vaccination uptake
[49, 52]. In the UK, the NIP goes hand in hand with
favourable attitudes toward vaccines, even when know-
ledge about them is poor, and the need for knowledge is
low [24, 40]. Hence a possible explanation of why parents
in the UK are not always aware of which and when spe-
cific vaccines are given. Much like in Denmark, the UK
public is adapted to national vaccination policies. This im-
plies that NIP vaccines are mostly trusted and considered
important – while non-NIP vaccines are not. One study
has shown that UK parents appreciate that the school-
based programme enables them to abdicate responsibility
to the authorities and that it creates equal health oppor-
tunities for children [45]. Outside schools, boys are gener-
ally less in contact with HCPs than girls [25].
Conclusion
Two factors play a major role in HPV vaccination uptake:
knowledge and structural incentives. When structural
barriers are low, as in Italy and the UK, acceptability is
high but knowledge does not necessarily follow. When
structural barriers are higher, as in France and Germany,
the need for knowledge and reassurance is higher. Inde-
pendently of the chosen national vaccination strategy,
however, parents and young people should be informed
about HPV related diseases in males and the benefits andrisks of accepting or rejecting HPV vaccination [53]. If
HPV vaccination is to reach the optimal effectiveness in
European populations, this poses a large responsibility on
public health authorities and HCPs to inform the public.
The education of HCPs about HPV and their direct recom-
mendation to their patients is particularly crucial to parents
in countries with opportunistic vaccination [54, 55].
Additional file
Additional file 1: Correlation analysis of reasons to accept (Q6),
have doubts or reject (Q7) HPV vaccination of sons.
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